Familial and sporadic pancreatic cancer share the same molecular pathogenesis

Familial Cancer

Volumn 14, Issue 1, 2015, Pages 95-103

  Norris, Alexis L ^a   Roberts, Nicholas J ^a   Jones, Siân ^a,b   Wheelan, Sarah J ^a   Papadopoulos, Nickolas ^a   Vogelstein, Bert ^a   Kinzler, Kenneth W ^a   Hruban, Ralph H ^a   Klein, Alison P ^a   Eshleman, James R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Personal Genome Diagnostics   (United States)

Author keywords

Cancer driver genes; Familial pancreatic cancer (FPC); Germline predisposition; Next generation sequencing (NGS); Pancreatic ductal adenocarcinoma (PDAC)

Indexed keywords

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; DNA LIBRARY; DNA SEQUENCE; FAMILIAL CANCER; FIRST DEGREE RELATIVE; GENE FREQUENCY; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN GENOME; MINIMAL RESIDUAL DISEASE; MISSENSE MUTATION; MOLECULAR PATHOLOGY; NONHUMAN; NONSENSE MUTATION; NUCLEIC ACID BASE SUBSTITUTION; ONSET AGE; OVERALL SURVIVAL; PANCREAS CANCER; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; RNA SEQUENCE; ADULT; AGED; CARCINOMA; DNA MICROARRAY; FEMALE; GENETIC PREDISPOSITION; GENETICS; HIGH THROUGHPUT SEQUENCING; MALE; MIDDLE AGED; PANCREAS CARCINOMA; PANCREAS TUMOR; VERY ELDERLY;

ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; CARCINOMA; CARCINOMA, PANCREATIC DUCTAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS;

EID: 84931031201     PISSN: 13899600     EISSN: 15737292     Source Type: Journal    
DOI: 10.1007/s10689-014-9755-y     Document Type: Article

References (56)

1. Howlader N NA, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) (2013) SEER Cancer Statistics Review, 1975–2010, National Cancer Institute. SEER web site
2. Petersen GM, Hruban RH (2003) Familial pancreatic cancer: where are we in 2003? J Natl Cancer Inst 95(3):180–181
3. Shi C, Hruban RH, Klein AP (2009) Familial pancreatic cancer. Arch Pathol Lab Med 133(3):365–374. doi:10.1043/1543-2165-133.3.365
4. Klein AP, Brune KA, Petersen GM et al (2004) Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 64(7):2634–2638
5. Hruban RH, Canto MI, Goggins M, Schulick R, Klein AP (2010) Update on familial pancreatic cancer. Adv Surg 44:293–311
6. Haddad A, Kowdley GC, Pawlik TM, Cunningham SC (2011) Hereditary pancreatic and hepatobiliary cancers. Int J Surg Oncol 2011:154673. doi:10.1155/2011/154673
7. Roberts NJ, Jiao Y, Yu J et al (2012) ATM mutations in patients with hereditary pancreatic cancer. Cancer Discovery 2(1):41–46. doi:10.1158/2159-8290.CD-11-0194
8. Hruban RH, Wilentz RE, Kern SE (2000) Genetic progression in the pancreatic ducts. Am J Pathol 156(6):1821–1825. doi:10.1016/S0002-9440(10)65054-7
9. Caldas C, Hahn SA, da Costa LT et al (1994) Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8(1):27–32. doi:10.1038/ng0994-27
10. Iacobuzio-Donahue CA, van der Heijden MS, Baumgartner MR et al (2004) Large-scale allelotype of pancreaticobiliary carcinoma provides quantitative estimates of genome-wide allelic loss. Cancer Res 64(3):871–875
11. Jones S, Zhang X, Parsons DW et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321(5897):1801–1806. doi:10.1126/science.1164368
12. Biankin AV, Waddell N, Kassahn KS et al (2012) Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491(7424):399–405. doi:10.1038/nature11547
13. Brune K, Abe T, Canto M et al (2006) Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. The American Journal of Surgical Pathology 30(9):1067–1076
14. Shi C, Klein AP, Goggins M et al (2009) Increased Prevalence of Precursor Lesions in Familial Pancreatic Cancer Patients. Clin Cancer Res 15(24):7737–7743. doi:10.1158/1078-0432.CCR-09-0004
15. Singhi AD, Ishida H, Ali S, et al (Submitted) A histomorphologic comparison of familial and sporadic pancreatic cancers
16. Bettegowda C, Sausen M, Leary RJ et al (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Trans Med 6(224):224-24. doi:10.1126/scitranslmed.3007094
17. Hall JM, Lee MK, Newman B et al (1990) Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250(4988):1684–1689
18. Bunyan DJ, Shea-Simonds J, Reck AC, Finnis D, Eccles DM (1995) Genotype-phenotype correlations of new causative APC gene mutations in patients with familial adenomatous polyposis. J Med Genet 32(9):728–731
19. Myrhoj T, Bisgaard ML, Bernstein I, Svendsen LB, Sondergaard JO, Bulow S (1997) Hereditary non-polyposis colorectal cancer: clinical features and survival. Results from the Danish HNPCC register. Scand J Gastroenterol 32(6):572–576
20. Goldstein AM, Chan M, Harland M et al (2006) High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 66(20):9818–9828. doi:10.1158/0008-5472.CAN-06-0494
21. Krainer M, Silva-Arrieta S, FitzGerald MG et al (1997) Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N Engl J Med 336(20):1416–1421. doi:10.1056/NEJM199705153362003
22. Raimondi S, Maisonneuve P, Lohr JM, Lowenfels AB (2007) Early onset pancreatic cancer: evidence of a major role for smoking and genetic factors. Cancer Epidemiol Biomarkers Prev 16(9):1894–1897. doi:10.1158/1055-9965.EPI-07-0341
23. Nicholls EM (1969) Somatic variation and multiple neurofibromatosis. Hum Hered 19(5):473–479
24. Knudson AG Jr (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68(4):820–823
25. Griffin CA, Morsberger L, Hawkins AL et al (2007) Molecular cytogenetic characterization of pancreas cancer cell lines reveals high complexity chromosomal alterations. Cytogenet Genome Res 118(2–4):148–156. doi:10.1159/000108295
26. Ouyang H, Mou L, Luk C et al (2000) Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am J Pathol 157(5):1623–1631. doi:10.1016/S0002-9440(10)64800-6
27. Jiao Y, Shi C, Edil BH et al (2011) DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331(6021):1199–1203. doi:10.1126/science.1200609
28. Li B, Dewey CN (2011) RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12:323. doi:10.1186/1471-2105-12-323
29. Thorvaldsdottir H, Robinson JT, Mesirov JP (2013) Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform 14(2):178–192. doi:10.1093/bib/bbs017
30. Internet] NCIhot (released April 2005, based on the November 2004 submission [cited 2014 Jun 24]) Surveillance Epidemiology and End Results (SEER) Program. SEER*Stat Database: Incidence—SEER 13 Regs Public-Use, Nov 2004 Sub (1973–2002 varying), National Cancer Institute DCCPS, Surveillance Research Program, Cancer Statistics Branch. http://www.seercancergov
31. Brune K, Hong SM, Li A et al (2008) Genetic and epigenetic alterations of familial pancreatic cancers. Cancer Epidemiol Biomarkers Prev 17(12):3536–3542. doi:10.1158/1055-9965.EPI-08-0630
32. Jiao Y, Yonescu R, Offerhaus GJ et al (2014) Whole-exome sequencing of pancreatic neoplasms with acinar differentiation. J Pathol 232(4):428–435. doi:10.1002/path.4310
33. Wu J, Jiao Y, Dal Molin M et al (2011) Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci USA 108(52):21188–21193. doi:10.1073/pnas.1118046108
34. Wu J, Matthaei H, Maitra A et al (2011) Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Science Transl Med 3(92):92-66. doi:10.1126/scitranslmed.3002543
35. Luttges J, Stigge C, Pacena M, Kloppel G (2004) Rare ductal adenocarcinoma of the pancreas in patients younger than age 40 years. Cancer 100(1):173–182. doi:10.1002/cncr.11860
36. Lal G, Liu G, Schmocker B et al (2000) Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res 60(2):409–416
37. James TA, Sheldon DG, Rajput A et al (2004) Risk factors associated with earlier age of onset in familial pancreatic carcinoma. Cancer 101(12):2722–2726. doi:10.1002/cncr.20700
38. Brandt A, Bermejo JL, Sundquist J, Hemminki K (2008) Age of onset in familial cancer. Ann Oncol 19(12):2084–2088. doi:10.1093/annonc/mdn527
39. Petersen GM, de Andrade M, Goggins M et al (2006) Pancreatic cancer genetic epidemiology consortium. Cancer Epidemiol Biomarkers Prev 15(4):704–710. doi:10.1158/1055-9965.EPI-05-0734
40. Eberle MA, Pfutzer R, Pogue-Geile KL et al (2002) A new susceptibility locus for autosomal dominant pancreatic cancer maps to chromosome 4q32-34. Am J Hum Genet 70(4):1044–1048. doi:10.1086/339692
41. Ozcelik H, Schmocker B, Di Nicola N et al (1997) Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet 16(1):17–18. doi:10.1038/ng0597-17
42. Fernandez E, La Vecchia C, D’Avanzo B, Negri E, Franceschi S (1994) Family history and the risk of liver, gallbladder, and pancreatic cancer. Cancer Epidemiol Biomarkers Prev 3(3):209–212
43. McWilliams RR, Bamlet WR, Rabe KG, Olson JE, de Andrade M, Petersen GM (2006) Association of family history of specific cancers with a younger age of onset of pancreatic adenocarcinoma. Clin Gastroenterol Hepatol 4(9):1143–1147. doi:10.1016/j.cgh.2006.05.029
44. Bartsch DK, Kress R, Sina-Frey M et al (2004) Prevalence of familial pancreatic cancer in Germany. Int J Cancer 110(6):902–906. doi:10.1002/ijc.20210
45. Lynch HT, Fitzsimmons ML, Smyrk TC et al (1990) Familial pancreatic cancer: clinicopathologic study of 18 nuclear families. Am J Gastroenterol 85(1):54–60
46. Lynch HT, Fusaro L, Lynch JF (1992) Familial pancreatic cancer: a family study. Pancreas 7(5):511–515
47. Ji J, Forsti A, Sundquist J, Lenner P, Hemminki K (2008) Survival in familial pancreatic cancer. Pancreatology 8(3):252–256. doi:10.1159/000134272
48. Ghadirian P, Boyle P, Simard A, Baillargeon J, Maisonneuve P, Perret C (1991) Reported family aggregation of pancreatic cancer within a population-based case-control study in the Francophone community in Montreal, Canada. Int J Pancreatol 10(3–4):183–196
49. Hruban RH, Petersen GM, Ha PK, Kern SE (1998) Genetics of pancreatic cancer. From genes to families. Surgical oncology clinics of North America 7(1):1–23
50. Silverman DT, Schiffman M, Everhart J et al (1999) Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer 80(11):1830–1837. doi:10.1038/sj.bjc.6690607
51. Permuth-Wey J, Egan KM (2009) Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis. Fam Cancer 8(2):109–117. doi:10.1007/s10689-008-9214-8
52. Couch FJ, Johnson MR, Rabe KG et al (2007) The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 16(2):342–346. doi:10.1158/1055-9965.EPI-06-0783
53. Al-Tassan N, Chmiel NH, Maynard J et al (2002) Inherited variants of MYH associated with somatic G:C– > T: A mutations in colorectal tumors. Nat Genet 30(2):227–232. doi:10.1038/ng828
54. FitzGerald MG, Harkin DP, Silva-Arrieta S et al (1996) Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci USA 93(16):8541–8545
55. Goldstein AM, Struewing JP, Chidambaram A, Fraser MC, Tucker MA (2000) Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst 92(12):1006–1010
56. Iacobuzio-Donahue CA, Velculescu VE, Wolfgang CL, Hruban RH (2012) Genetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencing. Clin Cancer Res 18(16):4257–4265